KURA News and Press, Kura Oncology Inc. From 08/09/20

Kura Oncology, Inc. (KURA) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Pete De Spain - Vice President of Investor Relations Troy Wilson - President & Chief Executive Officer Marc Grasso - Chief Financial Officer & Chief Business Officer ...

The following slide deck was published by Kura Oncology, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Image source: The Motley Fool. Kura Oncology, Inc.   (NASDAQ: KURA) Q2 2020 Earnings Call Aug 6, 2020 , 4:30 p.m. ET Operator Continue reading

The following healthcare companies have filed for mixed shelf offerings: More news on: Kura Oncology, Inc., Alphatec Holdings, Inc., Dynavax Technologies Corporation, Healthcare stocks news, , Read more ...

– Anticipate preliminary data presentation of menin inhibitor program, KO-539, at ASH – – Continued progress in registration-directed trial of tipifarnib in HRAS mutant HNSCC – – Opportunity to expand to HRAS and PI3K dependent tumors with potential t...

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual...

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2020 financial results after the clos...

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology & Oncolog...

– Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC – – Outcomes with approved therapies are poor, with reported median OS of 5-8 months, PFS of 2-3 months and ORR of 13-16% in the second line –...

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highlighting its drug candidate tipifarnib h...